Verona Pharma shares jump with Merck set to acquire company in $10 billion deal

Merck is acquiring Verona Pharma for approximately $10 billion, paying $107 per American depository share, a 23% premium, which caused Verona's shares to surge over 20%. This strategic acquisition significantly expands Merck's respiratory treatment portfolio, centered on Verona's FDA-approved COPD drug, Ohtuvayre, which analysts project could generate over $3 billion in annual peak sales. The deal is a key component of Merck's broader strategy to diversify its revenue streams and mitigate the anticipated impact of its blockbuster cancer drug Keytruda's patent expiration in 2028.

Analysis

Merck is executing a significant strategic acquisition of Verona Pharma for approximately $10 billion, a move designed to fortify its pipeline ahead of the 2028 patent expiration of its top-selling drug, Keytruda, which generated nearly $30 billion in revenue last year. The deal, priced at $107 per American depository share, represents a 23% premium to Verona's prior closing price and triggered an immediate surge of over 20% in Verona's stock. This transaction is Merck's largest since its 2023 acquisition of Prometheus Biosciences and underscores an aggressive M&A strategy to mitigate future revenue cliffs. The central asset in this acquisition is Ohtuvayre, a novel, FDA-approved treatment for COPD and the first new inhaled therapy for the condition in two decades. Since its commercial launch in August 2024, Ohtuvayre has already generated $42.3 million in revenue, and analyst projections from Jefferies forecast peak annual sales exceeding $3 billion. This potential revenue stream is critical for Merck to justify the acquisition cost and fill the gap left by Keytruda, complementing its existing cardio-pulmonary portfolio which was bolstered by the $11.5 billion Acceleron Pharma acquisition in 2021.

Key Decisions for Investors

• For Verona Pharma shareholders, the $107 per share offer represents a significant 23% premium, and investors should assess this price against the primary remaining risk of the deal's regulatory approval, which is expected by the end of 2025.
• For Merck investors, this acquisition should be viewed as a critical, though costly, strategic move to de-risk the company's significant revenue exposure to Keytruda's 2028 patent expiration, with the long-term success contingent on Ohtuvayre achieving its projected $3 billion-plus peak annual sales.
• The deal reinforces strong M&A appetite from large-cap pharma, suggesting that investors in biotech firms with late-stage, de-risked assets, particularly those mentioned in relation to Merck's strategy like MoonLake Immunotherapeutics, may see continued valuation support driven by acquisition potential.